What does QureBio do?
QureBio is a biopharmaceutical company developing bispecific and multispecific antibody and protein therapeutics, aimed at treating oncology, autoimmune, and inflammatory disorders.
How much did they raise?
The company raised nearly CNY 100M (approximately $14M) in a Series C1 round, with Efung Capital leading the investment.
What are their plans for the money?
The funds will be used to accelerate clinical trials and advance the pipeline of new antibody therapeutics, potentially addressing critical unmet medical needs in China and worldwide.
What have they achieved so far?
Founded in 2017, QureBio has built multiple proprietary technology platforms for antibody discovery and engineering, establishing a robust pipeline of drug candidates.
